Table 1.

Clinical Characteristics of Poor-Risk AML Patients in This Study

Characteristic No. of Patients
Age: median 54; range, 27 to 70 years old  
Gender: male = 23, female = 14 
  
De novo AML patients  27  
 Early relapse  11 
 Refractory AML  7  
 Second or greater relapse  
 Relapse post-BMT  4  
Duration of 1st remission <6 months* 20  
 Prior salvage therapy  15  
 Prior salvage responses 6  
Unfavorable cytogenetics 11  
Antecedent hematologic disease 10  
Unfavorable cytogenetics 7  
Total no. of patients  37 
Characteristic No. of Patients
Age: median 54; range, 27 to 70 years old  
Gender: male = 23, female = 14 
  
De novo AML patients  27  
 Early relapse  11 
 Refractory AML  7  
 Second or greater relapse  
 Relapse post-BMT  4  
Duration of 1st remission <6 months* 20  
 Prior salvage therapy  15  
 Prior salvage responses 6  
Unfavorable cytogenetics 11  
Antecedent hematologic disease 10  
Unfavorable cytogenetics 7  
Total no. of patients  37 
*

Duration of first remission, including six patients with prior salvage efforts.

Abnormalities of chromosome 5 and/or 7, or complex (≥3 abnormalities).

Refers to AML developing after myelodysplastic syndrome or myeloproliferative disorders (excluding chronic myeloid leukemia).

Close Modal

or Create an Account

Close Modal
Close Modal